Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 760

Sort by

Sort Order Select

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

Langerhans cell histiocytosis

Carlos Rodriguez-Galindo, Carl E. Allen

Blood (2020) 135 (16): 1319–1331.

https://doi.org/10.1182/blood.2019000934

Published: 2020

Includes: Supplemental data

Journal Articles

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Keri Keri Yang, Beth Lesher, PharmD, Eleanor Lucas, BA, Tony Caver, PhD, Boxiong Tang, MD PhD

Blood (2019) 134 (Supplement_1): 5881.

https://doi.org/10.1182/blood-2019-130896

Published: 2019

Journal Articles

Patient Profile and Treatment Patterns in a Commercially Insured Population with Follicular Lymphoma

Nathan H Fowler, MD, Yanni Hao, PhD, Stephen Lim, MD, Guifang Chen, PhD, Frank Li, PhD, Steve Arcona, PhD

Blood (2019) 134 (Supplement_1): 5880.

https://doi.org/10.1182/blood-2019-127237

Published: 2019

Journal Articles

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

Jing Xie, Alan Yong, Catherine Waweru, PhD, Thuy Anh Sorof, Ravi K Goyal, MS, Keith L Davis, MA, George Follows, Peter Hillmen, MD PhD

Blood (2019) 134 (Supplement_1): 5885.

https://doi.org/10.1182/blood-2019-123025

Published: 2019

Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule

Blood (2019) 134 (Supplement_1): 3989.

https://doi.org/10.1182/blood-2019-129829

Published: 2019

Journal Articles

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

Rachel Hu, MD, Wei Wei, MS, Kristen Gonter-Aubin, DO, Javier Pinilla Ibarz, MD PhD, Charlene C. Kabel, PharmD, Anthony R. Mato, MDMSCE, Yazan F. Madanat, MD, Sirin Khajavian, MD, Mazyar Shadman, MD, Ashley Hanlon, MD, Danielle M. Brander, MD, Jae H. Park, MD, Martin S. Tallman, MD, Brian T. Hill, MD

Blood (2019) 134 (Supplement_1): 4004.

https://doi.org/10.1182/blood-2019-126381

Published: 2019

Journal Articles

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Sattva S Neelapu, MD, Frederick L. Locke, MD, Nancy L Bartlett, MD, Lazaros J Lekakis, MD, Patrick M Reagan, MD, David B. Miklos, MD PhD, Caron A. Jacobson, MD MMSc, Ira Braunschweig, MD, Olalekan O. Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, Michael Crump, MD, John Kuruvilla, MD, Eric Van Den Neste, MD, Umar Farooq, MD, Lynn Navale, MS, Venita DePuy, PhD, Jenny J. Kim, MD MS, Christian Gisselbrecht, MD

Blood (2019) 134 (Supplement_1): 4095.

https://doi.org/10.1182/blood-2019-125792

Published: 2019

Journal Articles

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

Karin Ekstrom Ekstroem Smedby, Sara Ekberg, Sandra Eloranta, Gunilla Enblad, Mats Jerkeman, MD Professor, Per-Ola Andersson, MD PhD, Sara Harrysson, MD

Blood (2019) 134 (Supplement_1): 4111.

https://doi.org/10.1182/blood-2019-123785

Published: 2019

Journal Articles

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

Ariela Noy, MD, Timothy S. Pardee, MD PhD, Liana Nikolaenko, MD, Raphael Eric Steiner, MD, Jeremy S. Abramson, MD MMSc, Kieron Dunleavy, MD, Sanjeev Luther, MBA

Blood (2019) 134 (Supplement_1): 4087.

https://doi.org/10.1182/blood-2019-131563

Published: 2019

Journal Articles

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Oliver Tomkins, BMBS, MRCP, Joshua Bomsztyk, Helen McCarthy, MBBS, PhD, Jaimal Kothari, Dima El-Sharkawi, Charalampia Kyriakou, Guy Pratt, Ali Rismani, MBBS, Shirley D'Sa

Blood (2019) 134 (Supplement_1): 4016.

https://doi.org/10.1182/blood-2019-129212

Published: 2019

Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 4029.

https://doi.org/10.1182/blood-2019-123879

Published: 2019

Journal Articles

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

Hélène Deutsch, MD, Andre Baruchel, Joelle Guilhot, PhD, Arnaud Petit, MD PhD, Thierry Leblanc, MD, Yves Bertrand, MD, Brigitte Nelken, MD, Catherine Paillard, MD PhD, Cécile Verite, MD, Yves Réguerre, MD, Francoise Mechinaud, MD FRACP, Francois Guilhot, MD, Frederic Millot

Blood (2019) 134 (Supplement_1): 4147.

https://doi.org/10.1182/blood-2019-124060

Published: 2019

Journal Articles

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Amandeep Godara, MD, Denis Toskic, BS, Benjamin Rosenthal, BS, Cindy Varga, MD BSc, Adin Kugelmass, BSc, Ping Zhou, MD PhD, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4369.

https://doi.org/10.1182/blood-2019-127004

Published: 2019

Journal Articles

Results from an Expanded Access Program of Anti-CD3/CD7 Immunotoxin Combination (T-Guard®) for the Treatment of Steroid-Refractory Acute Gvhd

Lenneke F J Groningen, Christoph Groth, MD, Manita E J Bremmers, Eric G Hooren, Ypke V J M van Oosterhout, Nicole M A Blijlevens, Matthias Stelljes, Walter J F M van der Velden

Blood (2019) 134 (Supplement_1): 4553.

https://doi.org/10.1182/blood-2019-122923

Published: 2019

Journal Articles

Clostridium Difficile Infection Among Hematopoietic Stem Cell Transplant Recipients and Subsequent Development of Graft-Versus-Host Disease

Shanee Chung, MD, Yasser Abou Mourad, MD

Blood (2019) 134 (Supplement_1): 4494.

https://doi.org/10.1182/blood-2019-129663

Published: 2019

Journal Articles

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Waleed Ghanima, MD PhD, Marc Michel, Abderrahim Khelif, Bernadette Darne, Pal André Holme, PhDMD

Blood (2019) 134 (Supplement_1): 2358.

https://doi.org/10.1182/blood-2019-126975

Published: 2019

Journal Articles

Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents

Luciana Vinti, MD, Luisa Strocchio, MD, Barbara Buldini, MD PhD, Daniela Silvestri, Valentino Conter, MD, Pietro Merli, MD, Carmelo Rizzari, Rosanna Parasole, MD, Maddalena Paganin, PhD, Giuseppe Basso, MD PhD, Marco Zecca, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 2580.

https://doi.org/10.1182/blood-2019-131292

Published: 2019

Journal Articles

Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2019) 134 (Supplement_1): 2904.

https://doi.org/10.1182/blood-2019-122760

Published: 2019

Journal Articles

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Univ. Prof. Dr., Florian H. Heidel, Philippe Schafhausen, Martin Griesshammer, MD, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, MD, Stefani B. Parmentier, Nikolas von Bubnoff, Frank Stegelmann, MD, Angela Maurer, Jeremy Franklin, Martina Crysandt, MD, Deniz Gezer, Martin Hellmich, Tim H Brümmendorf, MD

Blood (2019) 134 (Supplement_1): 2944.

https://doi.org/10.1182/blood-2019-123985

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How I treat warm autoimmune hemolytic anemia

Langerhans cell histiocytosis

Systematic Literature Review on Global Real-World Treatment Patterns of Mantle Cell Lymphoma (MCL)

Patient Profile and Treatment Patterns in a Commercially Insured Population with Follicular Lymphoma

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis

A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma

Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden

A Phase II Clinical Trial of Cpi-613 (devimistat) in Patients with Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma with Rearrangements of MYC and BCL2 and/or BCL6

An Analysis from the WM UK Rory Morrison Registry: Waldenström's Macroglobulinaemia Patient Demographics, Disease Characteristics and Evolving Treatment Choices

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Imatinib in Children with Chronic Myeloid Leukemia in Chronic Phase: Long-Term Results of the French National Phase IV Trial

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Results from an Expanded Access Program of Anti-CD3/CD7 Immunotoxin Combination (T-Guard®) for the Treatment of Steroid-Refractory Acute Gvhd

Clostridium Difficile Infection Among Hematopoietic Stem Cell Transplant Recipients and Subsequent Development of Graft-Versus-Host Disease

Rituximab Yielded a Significantly Longer Response Compared to Placebo in Steroid Free Population - a Post Hoc Analysis of the Ritp Study

Long-Term Outcome of Relapsed Acute T-Lymphoblastic Leukemia (T-ALL) in Children and Adolescents

Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only